Evidence map›Paper›PMID 38838218›Full record

ArticleThe Journal of infectious diseases2024

Kinetics and Durability of Antibody and T-Cell Responses to SARS-CoV-2 in Children.

Megan A Files, Lauren Gentles, Leanne Kehoe, Amanda Adler, Kirsten Lacombe, Jane A Dickerson, Alexander Greninger, Alpana Waghmare, Tarayn Fairlie, Kimberly Pringle and 4 more

Abstract read
In one paragraph

Article in The Journal of infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Megan A FilesDepartment of Medicine, School of Medicine, University of Washington, Seattle, Washington.ORCID 0000-0002-5064-0490
Lauren GentlesBasic Sciences Division, Fred Hutchinson Cancer Center, Seattle, Washington.ORCID 0000-0002-2532-412X
Leanne KehoeDivision of Pediatric Infectious Diseases, Seattle Children's Research Institute, Seattle, Washington.ORCID 0009-0005-4940-4246
Amanda AdlerDivision of Pediatric Infectious Diseases, Seattle Children's Research Institute, Seattle, Washington.ORCID 0000-0002-2797-3385
Kirsten LacombeDivision of Pediatric Infectious Diseases, Seattle Children's Research Institute, Seattle, Washington.
Jane A DickersonDepartment of Laboratory Medicine and Pathology, School of Medicine, University of Washington, Seattle, Washington.ORCID 0000-0003-0033-2892
Alexander GreningerDepartment of Laboratory Medicine and Pathology, School of Medicine, University of Washington, Seattle, Washington.ORCID 0000-0002-7443-0527
Alpana WaghmareVaccine and Infectious Diseases Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.ORCID 0000-0003-2268-9470
Tarayn FairlieCoronavirus and Other Respiratory Viruses Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia.ORCID 0000-0001-9954-7185
Kimberly PringleCoronavirus and Other Respiratory Viruses Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia.ORCID 0000-0002-8927-8724
Claire M MidgleyCoronavirus and Other Respiratory Viruses Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia.ORCID 0000-0001-5196-4713
Melissa Briggs HagenCoronavirus and Other Respiratory Viruses Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia.ORCID 0000-0001-7359-9665
Janet A EnglundDivision of Pediatric Infectious Diseases, Seattle Children's Research Institute, Seattle, Washington.ORCID 0000-0003-1134-4178
Chetan SeshadriDepartment of Medicine, School of Medicine, University of Washington, Seattle, Washington.ORCID 0000-0003-2783-7540

Funding

Immune correlates of tuberculosis and non-tuberculosis infectious morbidity in Southern African HIV-exposed, uninfected infants.R01AI142670 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI POWIS, KATHLEEN · 2019 to 2023
$4.0M
CDC HHSChildren's Hospital FoundationNIH HHS
6 · The paper itself

Abstract

backgroundThe kinetics and durability of T-cell responses to SARS-CoV-2 in children are not well characterized. We studied a cohort of children aged 6 months to 20 years with COVID-19 in whom peripheral blood mononuclear cells and sera were archived at approximately 1, 6, and 12 months after symptom onset.

methodsWe compared antibody responses (n = 85) and T-cell responses (n = 30) to nucleocapsid (N) and spike (S) glycoprotein over time across 4 age strata: 6 months to 5 years and 5-9, 10-14, and 15-20 years.

resultsN-specific antibody responses declined over time, becoming undetectable in 26 (81%) of 32 children by approximately 1 year postinfection. Functional breadth of anti-N CD4+ T-cell responses also declined over time and were positively correlated with N-antibody responses (Pearson r = .31, P = .008). CD4+ T-cell responses to S displayed greater functional breadth than N in unvaccinated children and, with neutralization titers, were stable over time and similar across age strata. Functional profiles of CD4+ T-cell responses against S were not significantly modulated by vaccination.

conclusionsOur data reveal durable age-independent T-cell immunity to SARS-CoV-2 structural proteins in children over time following COVID-19 infection as well as S-antibody responses in comparison with declining antibody responses to N.

Indexed as

Antibodies, ViralCD4-Positive T-LymphocytesCOVID-19SARS-CoV-2Spike Glycoprotein, CoronavirusAdolescentAntibodies, NeutralizingChildChild, PreschoolCoronavirus Nucleocapsid ProteinsFemaleHumansInfantKineticsMalePhosphoproteinsAntibodies, NeutralizingAntibodies, ViralCoronavirus Nucleocapsid Proteinsnucleocapsid phosphoprotein, SARS-CoV-2PhosphoproteinsSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2childrenCOVID-19SARS-COV-2 nucleocapsid antibodySARS-COV-2 spike antibodyT-cell immunity to SARS-CoV-2

Identifiers

PMID38838218
PMCPMC11481334

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.